QuidelOrtho Corporation reported third quarter 2025 total revenue of $700 million, a 4.0% decrease compared to $727 million in the prior year period. Non-respiratory revenue was $588 million, up 5.0% as reported and 4.0% in constant currency; excluding Donor Screening, non-respiratory revenue grew 6.0% in constant currency. Labs revenue grew 5.0% as reported and 4.0% in constant currency. Respiratory revenue was $112 million, with the decline primarily due to a 63.0% decrease in COVID-19 revenue. GAAP operating expenses decreased by 6.0%, and non-GAAP operating expenses decreased by 7.0%. The period included a $701 million non-cash goodwill impairment charge, resulting in a GAAP net loss margin of (105%) and a GAAP operating margin of (101%). Adjusted EBITDA margin was 25.0%, a 180 basis point increase compared to the prior year. GAAP diluted loss per share was $10.78, while adjusted diluted earnings per share were $0.80. The company completed a debt refinancing during the quarter, improving financial flexibility.